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KRAS is one of the most frequently mutated genes in non-small cell lung cancer (NSCLC) 
and pancreatic ductal adenocarcinoma (PDAC) and therefore an appealing target for new 
targeted therapy approaches. However, all recent efforts to target KRAS-mutated tumors failed 
so far in clinical settings, but multiple potential approaches are under investigation. As direct 
targeting of KRAS is difficult, indirect approaches should be considered. Latest sequencing 
efforts have unraveled the mutational landscape of NSCLC and PDAC tumors. Next to KRAS 
mutations, a lot of other genes are found to be mutated within the same tumor. Both NSCLC 
and PDAC harbor recurrent functional mutations of the master DNA damage response (DDR) 
kinase ataxia telangiectasia mutated (ATM), a key kinase in homologous recombination (HR). 
Although mutations in HR genes predispose to the development of cancer by increased 
genomic instability, they also increase the dependence of cancer cells on other repair 
mechanisms and drive a tumor more sensitive to certain DNA damaging agents and other 
targeted therapies.  
Here we evaluated in two different Kras-mutant mouse models how ATM deficiency affects 
tumor progression and response to therapy. Two targeted therapy approaches could be 
established in ATM-deficient tumors, namely the PARP inhibitor olaparib as well as the ATR 
inhibitor VE-822. Taken together, our results provide a functional rationale to profile human 
tumors for disabling ATM mutations and for the use of PARP and ATR inhibitors to 
potentially improve treatment in ATM-mutant NSCLC and PDAC. 
 
